Differential expression patterns of AIP, UCKL1, and PKN1 genes in breast cancer of different molecular subtypes


  • L. Kovalevska R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • E. Kashuba R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • T. Zadvornyj R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • K. Astrid R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N. Lukianova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V. Сhekhun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology




AIP, bioinformatic analysis, breast cancer, expression pattern, molecular subtypes of breast cancer, PKN1, UCKL1


Summary. Background: Classification of breast cancer (BC) in the molecular subtypes had the enormous impact on the development of the individualized therapy. Nevertheless, there is a need for additional biomarkers that would help to refine molecular subtypes of BC and propose the therapeutic approach for each patient. Aim: To study differential expression patterns of AIP, UCKL1, and PKN1 genes in blood sera and tumor tissue of patients with BC of different molecular subtypes. Materials and Methods: The total extracellular RNA was isolated from serum of 26 BC patients. cDNAs was synthesized and quantitative polymerase chain reaction was performed. Also, immunohistochemical studies of UCKL, AIP and PKN1 were performed on deparaffined tissue sections. The study was supplemented by a bioinformatic analysis of the publicly available databases. Results: AIP and UCKL-1 extracellular mRNA levels were 100–1000-fold increased in blood sera of all BC patients, compared to the healthy donors. The highest levels were detected in the luminal A and HER2 (ERRB2) BC subtypes. The highest levels of PKN1 were detected blood sera of the patients with luminal B and basal subtypes; its expression levels were just 10–100-fold higher in BC samples compared to healthy donors. Conclusions: The UCKL1, AIP, PKN1 genes are overexpressed at the mRNA level in blood sera of BC patients compared to the sera of healthy individuals. Among three genes under study, only for the AIP gene, the pattern of extracellular mRNA expression in sera paralleled to protein expression in BC tissues of each specified molecular subtype.


Saeki K, Chang G, Kanaya N, et al. Mammary cell gene expression atlas links epithelial cell remodeling events to breast carcinogenesis. Commun Biol 2021; 4: 660. https://doi.org/10.1038/s42003-021-02201-2

Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23: 7350–60. https://doi.org/10.1200/JCO.2005.03.3845

Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. Int J Clin Exp Pathol 2015; 8: 8500–5.

Kumar B, Prasad M, Bhat-Nakshatri P, et al. Normal breast-derived epithelial cells with luminal and intrinsic subtype-enriched gene expression document interindividual differences in their differentiation cascade. Cancer Res 2018; 78: 5107–23. https://doi.org/10.1158/0008-5472.CAN-18-0509

Ades F, Zardavas D, Bozovic-Spasojevic I, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 2014; 32: 2794–803. https://doi.org/10.1200/JCO.2013.54.1870

Boulos F, Farra CG, Saad Aldin EM, et al. Hanging frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast. J Clin Pathol 2014; 67: 204–9. https://doi.org/10.1136/jclinpath-2013-201546

Bareche Y, Venet D, Ignatiadis M, et al. Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol 2018; 29: 895–902. https://doi.org/10.1093/annonc/mdy024

Fougner C, Bergholtz H, Norum JH, Sorlie T. Re-definition of claudin-low as a breast cancer phenotype. Nat Commun 2020; 11: 1787. https://doi.org/10.1038/s41467-020-15574-5

Waks AG, Winer EP. Breast cancer treatment: A review. JAMA 2019; 321: 288–300. https://doi.org/10.1001/jama.2018.19323

Yanovich G, Agmon H, Harel M, et al. Clinical proteomics of breast cancer reveals a novel layer of breast cancer classification. Cancer Res 2018; 78: 6001–10. https://doi.org/10.1158/0008-5472.CAN-18-1079

Hammerl D, Smid M, Timmermans AM, et al. Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin Cancer Biol 2018; 52: 178–88. https://doi.org/10.1016/j.semcancer.2017.11.003

Chekhun VF, Andriiv AV, Lukianova NY. Significance of iodine symporter for prognosis of the disease course and efficacy of neoadjuvant chemotherapy in patients with breast cancer of luminal and basal subtypes. Exp Oncol 2017; 39: 65–8.

Zhang Z, Tang P. Genomic pathology and biomarkers in breast cancer. Crit Rev Oncog 2017; 22: 411–26. https://doi.org/10.1615/CritRevOncog.v22.i5-6.60

Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology 2017; 49: 166–71. https://doi.org/10.1016/j.pathol.2016.11.006

Trivellin G, Korbonits M. AIP and its interacting partners. J Endocrinol 2011; 210: 137–55. https://doi.org/10.1530/JOE-11-0054

Stojanovic M, Wu Z, Stiles CE, et al. Circulating aryl hydrocarbon receptor-interacting protein (AIP) is independent of GH secretion. Endocr Connect 2019; 8: 326–37. https://doi.org/10.1530/EC-19-0082

Schernthaner-Reiter MH, Trivellin G, Stratakis CA. Interaction of AIP with protein kinase A (cAMP-dependent protein kinase). Hum Mol Genet 2018; 27: 2604–13. https://doi.org/10.1093/hmg/ddy166

Tuominen I, Heliovaara E, Raitila A, et al. AIP inactivation leads to pituitary tumorigenesis through defective Galphai-cAMP signaling. Oncogene 2015; 34: 1174–84. https://doi.org/10.1038/onc.2014.50

Gullickson G, Ambrose EC, Hoover RG, Kornbluth J. Uridine cytidine kinase like-1 enhances tumor cell proliferation and mediates protection from natural killer-mediated killing. Int J Immunol Immunother 2016; 3. 10.23937/2378-3672/1410018. https://doi.org/10.23937/2378-3672/1410018

Przybyla T, Sakowicz-Burkiewicz M, Maciejewska I, et al. Suppression of ID1 expression in colon cancer cells increases sensitivity to 5-fluorouracil. Acta Biochim Pol 2017; 64: 315–22. https://doi.org/10.18388/abp.2016_1421

Buivydiene A, Liakina V, Valantinas J, et al. expression levels of the uridine-cytidine kinase like-1 protein as a novel prognostic factor for hepatitis C virus-associated hepatocellular carcinomas. Acta Naturae 2017; 9: 108–14.

Buivydiene A, Liakina V, Kashuba E, et al. Impact of the Uridine(-)Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the development of hepatocellular carcinoma in cirrhotic chronic hepatitis C patients-a pilot study. Medicina (Kaunas) 2018; 54: 67. https://doi.org/10.3390/medicina54050067

Kashuba E, Kashuba V, Sandalova T, et al. Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyltransferase. BMC Cell Biol 2002; 3: 23. https://doi.org/10.1186/1471-2121-3-23

Su C, Deaton RA, Iglewsky MA, et al. PKN activation via transforming growth factor-beta 1 (TGF-beta 1) receptor signaling delays G2/M phase transition in vascular smooth muscle cells. Cell Cycle 2007; 6: 739–49. https://doi.org/10.4161/cc.6.6.3985

Collazos A, Michael N, Whelan RD, et al. Site recognition and substrate screens for PKN family proteins. Biochem J 2011; 438: 535–43. https://doi.org/10.1042/BJ20110521

Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I. The Pyrin inflammasome in health and disease. Front Immunol 2019; 10: 1745. https://doi.org/10.3389/fimmu.2019.01745

Attarha S, Saini RK, Andersson S, et al. PKN1 modulates TGFbeta and EGF signaling in HEC-1-A endometrial cancer cell line. Onco Targets Ther 2014; 7: 1397–1408. https://doi.org/10.2147/OTT.S65051

Tan PH, Ellis I, Allison K, et al. WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast. Histopathology 2020; 77: 181–5. https://doi.org/10.1111/his.14091

Kovalevska LM, Zadvornyj TV, Malysheva TA, et al. Study on relative gene expression levels in tumor tissue and in blood serum of cancer patients. Oncologiya 2021, 23: 149–53 (in Ukrainian). https://doi.org/10.32471/oncology.2663-7928.t-23-3-2021-g.9761

Di Vizio D, Morello M, Dudley AC, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012; 181: 1573–84. https://doi.org/10.1016/j.ajpath.2012.07.030

Minciacchi VR, Freeman MR, Di Vizio D. Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev Biol 2015; 40: 41–51. https://doi.org/10.1016/j.semcdb.2015.02.010

Sadik N, Cruz L, Gurtner A, et al. Extracellular RNAs: a new awareness of old perspectives. Methods Mol Biol 2018; 1740: 1–15. https://doi.org/10.1007/978-1-4939-7652-2_1

Yuan T, Huang X, Woodcock M, et al. Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep 2016; 6: 19413. https://doi.org/10.1038/srep19413

Savelyeva AV, Kuligina EV, Bariakin DN, et al. Variety of RNAs in peripheral blood cells, plasma, and plasma fractions. Biomed Res Int 2017; 2017: 7404912. https://doi.org/10.1155/2017/7404912

Jung YW, Shim JI, Shim SH, et al. Global gene expression analysis of cell-free RNA in amniotic fluid from women destined to develop preeclampsia. Medicine (Baltimore) 2019; 98: e13971. https://doi.org/10.1097/MD.0000000000013971

Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. Science 2015; 347: 1260419. https://doi.org/10.1126/science.1260419

Uhlen M, Zhang C, Lee S, et al. A pathology atlas of the human cancer transcriptome. Science 2017; 357: eaan2507. https://doi.org/10.1126/science.aan2507

Kashuba EV, Gradin K, Isaguliants M, et al. Regulation of transactivation function of the aryl hydrocarbon receptor by the Epstein-Barr virus-encoded EBNA-3 protein. J Biol Chem 2006; 281: 1215–23. https://doi.org/10.1074/jbc.M509036200

Ozkaya HM, Comunoglu N, Sayitoglu M, et al. Germline mutations of aryl hydrocarbon receptor-interacting protein (AIP) gene and somatostatin receptor 1-5 and AIP immunostaining in patients with sporadic acromegaly with poor versus good response to somatostatin analogues. Pituitary 2018; 21: 335–46. https://doi.org/10.1007/s11102-018-0876-4

Lloyd C, Grossman A. The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas. Endocrine 2014; 46: 387–96. https://doi.org/10.1007/s12020-013-0125-6




How to Cite

Kovalevska, L., Kashuba, E., Zadvornyj, T., Astrid, K., Lukianova, N., & Сhekhun V. (2023). Differential expression patterns of AIP, UCKL1, and PKN1 genes in breast cancer of different molecular subtypes. Experimental Oncology, 43(4), 298–305. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.17067



Original contributions

Most read articles by the same author(s)

1 2 > >>